Finally, a platform trial architecture spanning HF and cardio-oncology domains can evaluate EGCG alone vs. combinations (e.g., EGCG + statin, EGCG + SGLT2i, EGCG + FXa inhibition in PAR-2-high states), with embedded multi-omics (plasma proteomics, metabolomics, cfRNA) and AI-driven multimodal fusion (imaging + omics + PK) to derive predictive response signatures and refine dosing/regimen selection for phase III. This evidence concerns the gene F2RL1 and hydrops fetalis.